Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Orencia (abatacept) / BMS

NCT02758769: Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

Completed

N/A

303

Japan

ORENCIA Subcutaneous Injection, Abatacept

Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd

Rheumatoid Arthritis

10/19

11/23

TIGHT, NCT03188081: A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept

Completed

N/A

171

Europe

Bristol-Myers Squibb

Rheumatoid Arthritis

08/20

NCT05170672: Expanded Access for Abatacept

No Longer Available

N/A

Europe, US

Abatacept

Bristol-Myers Squibb

ChiCTR2000036282: A prospective, double-blind, positive control study of abatacept in the treatment of high-risk patients with dermatomyositis and rapidly progressing interstitial pneumonia

Not yet recruiting

N/A

The initial dose was 10 mg/kg per month, and the intravenous infusion treatment of the treatment group was started by OW for 3 months. ;Using a light-shielding simulation bag that was completely consistent with the appearance and measurement of Abatacept, intravenous infusion was started for the placebo group at 0W. The infusion conditions were exactly the same as those in the treatment group and lasted for 3 months.

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shenkang Clinical Three-year Innovation Project Fund

dermatomyositis

NCT04377867: New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

Recruiting

N/A

RoW

Abatacept Injection [Orencia]

Marmara University, The Scientific and Technological Research Council of Turkey

LRBA Deficiency, CTLA4 Haploinsufficiency

07/22

01/23

PADIRRA, NCT04343378: Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis

Recruiting

N/A

Europe

University Hospital, Rouen

Rheumatoid Arthritis

06/24

POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting

N/A

5000

Canada, US

The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab

Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome

05/24

07/24

NCT06418529: A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Active, not recruiting

N/A

20000

tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab

Pfizer

Rheumatoid Arthritis

07/24

NCT05782335: Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

Recruiting

N/A

Hospital for Special Surgery, New York

Rheumatoid Arthritis

10/24

04/25

KOBIO, NCT01965132: Korean College of Rheumatology Biologics and Targeted Therapy Registry

Recruiting

N/A

10000

RoW

Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib

Seoul National University Hospital

Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis

12/29

06/30

SurviTreat, NCT03440892: Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Recruiting

N/A

2500

Europe

methotrexate, sulfasalazine, Salazopyrin, abatacept, Orencia, tocilizumab, RoActemra, tofacitinib/baricitinib, Xeljanz/Olumiant

Vastra Gotaland Region

Rheumatoid Arthritis

01/25

Arthritis, NCT05062421: Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid .

Recruiting

N/A

540

Europe

FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla

Arthritis, Rheumatoid

12/26

NCT01357668: An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Recruiting

N/A

800

Europe, Canada, US, RoW

Bristol-Myers Squibb

Juvenile Idiopathic Arthritis

01/29

NCT01088360: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)

Active, not recruiting

N/A

20000

Bristol-Myers Squibb, National Data Bank for Rheumatic Diseases (NDB)

Rheumatoid Arthritis

06/29

RCVRIC, NCT03187444: Cardiovascular Risk and Chronic Inflammatory Rheumatism

Active, not recruiting

N/A

200

Europe

Examinations

University Hospital, Clermont-Ferrand

Rheumatology, Cardiovascular Diseases, Arthritis, Rheumatoid, Spondyloarthritis

10/36

04/37



	Diseases Companies Products Productz Mechanisms of Action Sites